News

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...
Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...
Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...
Kepler Capital analyst Nicolas Pauillac maintained a Hold rating on Sanofi on July 10 and set a price target of €95.00. The company’s shares closed yesterday at $98.70. Elevat ...
Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...
Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.
Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.
Transplants can be life-saving – but for many, the journey doesn’t end there. Up to 40% of people receiving a stem cell or bone marrow transplant will go on to develop a serious complication known as ...
Sanofi is sponsoring the event for the second year in a row, which brings together 1,000 transplant recipients and live donors to compete.
Aide mémoire Paris, France - June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second ...
NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ:SNY). Such investors are advised to cont ...
Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 potential. Click for more on SNY and BPMC.